| Infliximab treatment for a patient with refractory Kawasaki disease |
|
Hyo-Jung Yu, Soo-Jin Lee, Sejung Sohn |
|
Department of Pediatrics, College of Medicine, Ewha Womans University, Seoul, Korea |
| Infliximab으로 치료한 난치성 가와사끼병 1례 |
|
유효정, 이수진, 손세정 |
|
이화여자대학교 소아과학교실 |
Correspondence:
Sejung Sohn, Email: sohn@ewha.ac.kr
|
|
|
|
|
| Abstract |
|
Intravenous immunoglobulin (IVIG) infusion is an effective therapy for acute Kawasaki disease (KD). Nonetheless, approximately 10 percent to 20 percent of patients have persistent or recrudescent fever despite IVIG treatment, leading to a higher risk for coronary artery aneurysms (CAA). This unresponsiveness may pose a challenge to the clinicians. Tumor necrosis factor-α levels are elevated in the acute phase of the disease, especially in patients who develop CAA. We report a 10-month-old male with KD who failed to respond to multiple doses of IVIG and methylprednisolone and who then was treated with infliximab (5 mg/kg single dose). After infliximab treatment, he became afebrile with normalization of inflammatory markers and no further progression of CAA. |
| Key Words:
Mucocutaneous lymph node syndrome , Tumor necrosis factor-α , Infliximab |
|
PDF Links
Download Citation
